Novo Nordisk’s Ozempic could be among the targets of Medicare pricing negotiations for 2027 – Novo Nordisk (NYSE:NVO)
The U.S. government’s recent push to negotiate drug prices under Medicare has sparked speculation about which drugs might be the subject of the next round of negotiations, scheduled for 2027.…